91㽶Ƶ To Discuss Potential Implications of Brexit on Clinical Supply
Mr. Young’s presentation, on Thursday, March 15 at 9:30 a.m., is entitled “Countdown to Brexit: Critical Supply Chain Pressure Tests,” and will explore the potential implications of the U.K.’s exit from the European Union as they relate to existing and future clinical supply operations. He will explore potential areas of risk within the supply chain, including key questions that sponsors should consider as they prepare for Brexit.
In his role as Director, Quality at 91㽶Ƶ’s Bolton, U.K., clinical supply facility, Mr. Young has overall responsibility for quality. He has over 20 years’ experience in the pharmaceutical industry, with prior roles in laboratories, production support, and quality assurance and control, where he has led facilities upgrades and system deployments. He is an Investigational Medicinal Products Qualified Person, and has a bachelor’s degree in biomedical chemistry, with further education in environmental analytical science and industrial pharmaceutical studies.
To arrange a meeting with Mr. Young at the event or afterward, please contact Richard Kerns at NEPR: [email protected].
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 91㽶Ƶ
91㽶Ƶ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 91㽶Ƶ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91㽶Ƶ employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. 91㽶Ƶ is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com